Welcome to our dedicated page for Exscientia Plc news (Ticker: EXAI), a resource for investors and traders seeking the latest updates and insights on Exscientia Plc stock.
Exscientia Plc (EXAI) is a pioneer in AI-driven drug discovery, transforming pharmaceutical research through automated small molecule design. This page serves as the definitive source for tracking the company's latest developments, offering investors and industry observers timely updates on its groundbreaking work.
Access comprehensive coverage of financial results, research milestones, and strategic partnerships that define Exscientia's progress. Our curated news collection includes press releases on clinical advancements, technology innovations, and regulatory developments essential for understanding the company's trajectory.
Key updates feature Exscientia's AI-optimized drug candidates, collaborations with leading pharmaceutical organizations, and insights into their automated discovery platform. The resource is particularly valuable for tracking how machine learning accelerates compound design while maintaining rigorous quality standards.
Bookmark this page for efficient monitoring of Exscientia's contributions to biopharmaceutical innovation. Return regularly to stay informed about how their AI-first approach continues to reshape drug development timelines and methodologies.
Exscientia (NASDAQ: EXAI) showcased significant advancements in precision medicine at the AACR Annual Meeting 2023, held from April 14-19 in Orlando, FL. The company presented four posters highlighting its innovative approaches, including a unique adenosine biomarker aimed at enhancing patient treatment responses. Key findings include the development of the adenosine burden score (ABS) that correlates with patient responses to therapies. Exscientia also reported progress in its first-in-human study of EXS21546, an A2A receptor antagonist, moving into a Phase 1/2 trial targeting renal and lung cancers. The success of these initiatives underlines Exscientia's commitment to leveraging AI for drug development and patient outcomes.
The report titled Global Cardiovascular Partnering 2016-2023, released by ResearchAndMarkets.com, analyzes cardiovascular disease deals from major pharmaceutical and biotechnology firms worldwide since 2016. Key insights include trends in cardiovascular partnering, financial deal terms, and structures.
It evaluates over 850 cardiovascular deals, detailing upfront payments, milestone payments, and royalties. The report is segmented to provide valuable benchmarking and analysis, including an overview of leading dealmakers and the financial metrics of significant agreements. This resource aims to inform prospective dealmakers in cardiovascular technology and product commercialization.
Exscientia plc (NASDAQ: EXAI) announced substantial developments in its pipeline and partnerships, as well as financial results for Q4 and FY 2022. Key highlights include a major collaboration with Sanofi, initiation of the Phase 1/2 IGNITE study of A2A receptor antagonist EXS21546, and the entry of EXS4318 into clinical trials by Bristol Myers Squibb. Financially, revenue for FY 2022 was $32.9 million, slightly down from $33.0 million in FY 2021. R&D expenses surged to $155.6 million, reflecting investments in the pipeline. The company ended 2022 with $610.9 million in cash and cash equivalents, down from $678.9 million in 2021.
Exscientia plc (Nasdaq: EXAI) plans to report its fourth quarter and full year financial results for the period ending December 31, 2022 on March 23, 2023. The announcement will be made before the opening of U.S. markets. Following this, a conference call and webcast will occur at 12:30 p.m. GMT / 8:30 a.m. EDT to discuss the results and provide a business update. Investors can access the live event via the company’s website or by dialing designated numbers for the U.S., U.K., and international participants.
Exscientia plc (NASDAQ: EXAI) announced four abstracts accepted for presentation at the AACR Annual Meeting 2023 from April 14-19, 2023, in Orlando, FL. Highlights include innovations in precision oncology and details on the A2A receptor antagonist, EXS21546, targeting adenosine pathways. The studies showcase Exscientia's advanced capabilities in functional precision medicine and aim to improve patient outcomes. Key presentations will cover topics like predicting cancer patient responses and developing reversible LSD1 inhibitors, which may benefit small-cell lung cancer treatment.
Exscientia plc (NASDAQ: EXAI) announced two new drug candidates, EXS74539 and EXS73565, designed for precision oncology. Both candidates are currently in IND-enabling studies, showcasing Exscientia's ability to tackle complex drug design challenges. The company aims to have four clinical-stage molecules by 2024. Notably, both compounds meet critical design goals of potency and selectivity, with each offering promising potential for patient benefit. EXS74539 targets brain metastases with favorable in vivo data, while EXS73565 demonstrates good pharmacokinetics and reduced toxicity risks. Exscientia retains all rights to these candidates following a collaboration with Bristol Myers Squibb.
Moelis & Company (NYSE: MC) announced management changes effective October 1, 2023. Elizabeth Crain, a Founding Partner and COO since 2007, has been appointed Vice Chair. She will lead critical strategic initiatives and client sponsorship globally. Kate Pilcher Ciafone, previously COO of Investment Banking since 2019, has been promoted to COO, taking over from Crain. Both leaders bring extensive experience in investment banking, aiming to drive the firm’s growth and strategic vision. Crain's leadership, recognized by Barron’s as one of the 100 Most Influential Women in U.S. Finance, strengthens Moelis’s commitment to delivering high-quality advice to clients worldwide.
Exscientia and Charité – Universitätsmedizin Berlin have announced a collaboration to enhance Exscientia's AI-driven precision medicine platform for treating haematological cancers. This partnership will assess the platform's ability to identify effective therapies through prospective evaluations of patient samples against a range of marketed drugs.
The collaboration builds on previous successful outcomes from the EXALT-1 trial, which demonstrated improved treatment recommendations for late-stage cancer patients. Charité will also create a unique biobank of live tissue samples, facilitating further research and development of personalized treatments.
Rallybio Corporation (Nasdaq: RLYB) announces significant progress in its clinical trials, particularly with RLYB212, an anti-HPA-1a monoclonal antibody, which achieved proof-of-concept by rapidly eliminating transfused platelets in HPA-1a negative subjects. The multiple dose cohort study for RLYB212 is now enrolling, with results expected in Q4 2023. The company also continues its Phase 1 study of RLYB116, targeting complement-related diseases. Financially, Rallybio reported a net loss of $66.7 million for 2022 but has $169 million in cash reserves, providing a runway into Q1 2025. Future data and collaborations are anticipated to drive further developments.
Exscientia plc (Nasdaq: EXAI) announced participation in several investor conferences in March 2023. Key events include the Morgan Stanley EMEA HealthTech Conference on
